Breaking News

BMS to Close Libertyville Viral Vector Production Facility

Plans to transfer vector production capabilities to its Devens, MA facility.

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol Myers Squibb plans to close its viral vector production facility in Libertyville, IL according to a BMS spokesperson as reported by FirstWord Pharma. BMS acquired the facility from Novartis in 2023.

The facility and its operations have capabilities to produce viral vector for Bristol Myers Squibb’s two CAR T cell therapies, Breyanzi to treat certain types of lymphomas and Abecma to treat multiple myeloma. The company plans to transfer vector production capabilities to its Devens, MA facility.

The company’s restructuring initiative announced in 2024 aims to save $1.5 billion. A recent expansion of the program aims to save an additional $2 billion by the end of 2027 through organizational changes and efforts to enhance operational efficiency.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters